Vaccine from Moderna has more advantages

Vaccine from Moderna has more advantages. Last week, the German BioNTech company and Pfizer also announced that the effectiveness of the co-developed COVID-19 vaccine has reached 90%. Russia later announced that the country’s “Sputnik V” (Sputnik V) vaccine has an effective rate of 92%. If the results are still as impressive as the trials, the Moderna vaccine may have a greater advantage over the Pfizer vaccine.

Because the storage conditions of Pfizer’s vaccines are very demanding, the period from the production plant to the patient’s vaccination needs to be kept in an ultra-low temperature freezing state of -70°C to -80°C.
And Moderna said that it has improved the shelf life and stability of its vaccine, which means it can be stored at a standard refrigeration temperature of 2°C to 8°C for 30 days. If it is kept under -20℃, it can be stored for six months for transportation and long-term storage.

Such a preservation environment will benefit more people in more regions, both in terms of technology and transportation costs.

In addition, there is still a question mark about Pfizer vaccine, that is, whether it can prevent serious diseases. The Moderna results released by the Independent Data Security Monitoring Committee are even more exciting at this point. The 11 participants who developed severe symptoms of COVID-19 disease during the trial were all in the placebo group.

Unlike the Pfizer vaccine, the inclusion of high-risk groups and the elderly in the Moderna trial proves that the vaccine can protect the people most susceptible to the disease. In addition, the results also show that the vaccine is effective for people from different ethnic backgrounds.